For comments, suggestions
Created with Raphaël 2.1.0 18.05.2018 Filing date 02.01.2020 Validation fee payment 31.05.2020 (A1) Patent application published

Patent not validated (the request for validation was not submitted on time)


(210)Number of the EPO application18728541
(220)Filing date of the EPO application2018.05.18
(80)EPO patent specification publication (B)EPB nr. 34/2022, 2022.08.24
(110)EPO patent number3630723
(21)Number of the applicatione 2020 0317
(71)Name(s) of applicant(s), code of the countryJanssen Pharmaceuticals, Inc., US;
Katholieke Universiteit Leuven, BE;
(72)Name(s) of inventor(s), code of the countryBONFANTI Jean-François, FR;
KESTELEYN Bart Rudolf Romanie, BE;
BARDIOT Dorothée Alice Marie-Eve, BE;
MARCHAND Arnaud Didier M, BE;
COESEMANS Erwin, BE;
FORTIN Jérôme Michel Claude, FR;
MERCEY Guillaume Jean Maurice, FR;
RABOISSON Pierre Jean-Marie Bernard, BE;
(73)Name(s) of owner(s), code of the countryJANSSEN Pharmaceuticals Inc., US;
Katholieke Universiteit Leuven, BE;
(54)Title of the inventionSUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS
(13)Kind-of-document code A1
(51)International Patent Classification C07D 209/08 (2006.01.01); A61K 31/403 (2006.01.01); A61P 31/12 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2020.05.31
(30)Priority17172237, 2017.05.22, EP
(86)International applicationPCT/EP2018/063028, 2018.05.18
(87)International publicationWO 2018/215315, 2018.11.29
Up
/Inventions/details/3630723